Vimarsana
Biggest News Aggregation in the World

Page 6 - Nextcell Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nextcell Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nextcell Pharma Today - Breaking & Trending Today

Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd - Vimarsana News

Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd

Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd The upcoming Phase III trial with Diamyd in new-onset type 1 diabetes will be based on the first precision medicine approach in the field. The trial is designed to confirm the effect and safety of Diamyd in individuals recently diagnosed with type 1 diabetes who carry the genetic HLA DR3-DQ2 haplotype. The Phase III trial is designed to enroll approximately 330 individuals aged 12 to 28, recently diagnosed with type 1 diabetes, who carry the HLA DR3-DQ2 haplotype. This patient population is based...

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes - Vimarsana News

Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes

(1) STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes (T1D) through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative (TOMI) T1D integrated database. The Phase III trial evaluated the use of the diabetes vaccine Diamyd , an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance ...